onc Videos

Videos

Kevin Kalinsky, MD, MS, Director, Glenn Family Breast Center, Winship Cancer Institute at Emory University

Videos

Right Sizing HR-Positive Breast Cancer Adjuvant Therapy With Genomic Risk Stratifying Assays

10/28/2022

Kevin Kalinsky, MD, MS, shares his insights on right sizing adjuvant therapy for HR-positive breast cancer with the use of genomic risk stratifying assays.

Kevin Kalinsky, MD, MS, shares...

10/28/2022

Oncology

Sponsored

Videos

Part 5: Current Challenges and Unmet Needs in Targeted Treatment Selection

10/27/2022

Drs Langer, Lisberg, Bazhenova, and Nagasaka conclude their discussion by considering remaining challenges in biomarker testing in NSCLC and unresolved questions about the appropriate place and future prospects of targeted treatments,...

Drs Langer, Lisberg, Bazhenova,...

10/27/2022

Oncology

Sponsored

Videos

Part 4: Antibody-Drug Conjugates (ADCs): Overview and Treatment Sequence

10/27/2022

After sharing their basic approaches to treating actionable mutations, our 4 panelists now share their perspectives on the place of ADCs in advanced/metastatic NSCLC and on the future prospects of ADCs as a component of combination regimens...

After sharing their basic...

10/27/2022

Oncology

Sponsored

Videos

Part 3: Review of Targeted Therapies for Lung Cancer with Actionable Mutations

10/27/2022

Drs Langer, Lisberg, Bazhenova, and Nagasaka describe their use of targeted therapies in patients with the most common mutations and fusions. They share their experiences with these agents both in clinical trials and in clinical practice.

Drs Langer, Lisberg, Bazhenova,...

10/27/2022

Oncology

Sponsored

Videos

Part 2: Biomarker Testing at the Time of Disease Progression

10/27/2022

Having considered the basics of biomarker testing, our panelists turn their attention to challenges of biomarker testing at the time of NSCLC progression and share their perspectives on the current NCCN guidelines for biomarker testing and...

Having considered the basics of...

10/27/2022

Oncology

Sponsored

Videos

Part 1: Highlights–Importance of Biomarker Testing

10/27/2022

Four distinguished oncologists – Drs Corey Langer, Aaron Lisberg, Lyudmila Bazhenova, and Misako Nagasaka – describe biomarker testing in patients with advanced/metastatic NSCLC treated at their institutions. Topics include their use of...

Four distinguished oncologists –...

10/27/2022

Oncology

Videos

Novel CELMoD Agents for Multiple Myeloma: Iberdomide and Mezigdomide

10/21/2022

Paul Richardson, MD, provides an update on the treatment of multiple myeloma with novel CELMoD agents iberdomide and mezigdomide at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.

Paul Richardson, MD, provides an...

10/21/2022

Oncology

Videos

Outpatient Combination Therapy in Patients With Newly Diagnosed AML

10/21/2022

Keith Pratz, MD, provides insights into navigating outpatient combination therapy in newly diagnosed acute myeloid leukemia at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.

Keith Pratz, MD, provides...

10/21/2022

Oncology

Videos

Treatment for Advanced and Recurrent Endometrial Cancer

10/20/2022

BJ Rimel, MD, shares important considerations for clinicians when caring for patients with advanced and recurrent endometrial cancer, a topic she presented at the 2022 GDU Women’s Oncology virtual meeting.

BJ Rimel, MD, shares important...

10/20/2022

Oncology

Videos

Emerging Opportunities for the Treatment of Cervical Cancer

10/20/2022

Ritu Salani, MD, reviews new and upcoming opportunities for the treatment of patients with cervical cancer, a topic she presented at the 2022 GDU Women’s Oncology virtual meeting.

Ritu Salani, MD, reviews new and...

10/20/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology